Jomi Oommen, Judy Chen, Shan Wang, Thomas Caraccio, Adel Hanna
{"title":"Droxidopa for Hypotension of Different Etiologies: Two Case Reports.","authors":"Jomi Oommen, Judy Chen, Shan Wang, Thomas Caraccio, Adel Hanna","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Orthostatic hypotension is defined as a decrease in systolic blood pressure of at least 20 mmHg or a decrease in diastolic blood pressure of at least 10 mmHg (or both), within three minutes of moving from a supine to an upright or standing position. Droxidopa is a synthetic amino acid analog that is directly metabolized to norepinephrine by dopa-decarboxylase, subsequently providing alpha and beta-agonist effects to increase blood pressure. It is indicated in the treatment of neurogenic orthostatic hypotension caused by primary autonomic failure that is associated with Parkinson disease, multi-system atrophy, pure autonomic failure, dopamine beta-hydroxylase deficiency, and/or non-diabetic autonomic neuropathy. In addition, it has been studied in other disease states, such as diabetic autonomic neuropathy-associated orthostatic hypotension and supine hypotension. We report on two cases of off-label droxidopa use. The first case was for diabetic autonomic neuropathy-associated orthostatic hypotension, and the second case was for hypotension due to autonomic dysfunction associated with rheumatoid arthritis. Although the outcomes differed in each case, this article contributes to the literature demonstrating that droxidopa may have varying effects in treating orthostatic hypotension of non-neurogenic etiology.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"125-144"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385736/pdf/ptj4403125.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019427","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Routine Use of Vitamin K in the Treatment of Cirrhosis-Related Coagulopathy: Is it A-O-K? Maybe Not, We Say.","authors":"Sarah M Aldrich, Randolph E Regal","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Historically, coagulopathy related to cirrhosis has been managed primarily as a bleeding disorder. However, several recent studies have shown that patients with cirrhosis have an increased risk of both bleeding and clotting. These coagulopathic changes are a result of the decreased synthetic capabilities of the cirrhotic liver. Vitamin K is often given to correct prolonged prothrombin times (PT) in patients with cirrhosis. However, this practice is not well defined and its effectiveness is questionable. The objective of our literature review is to determine the effectiveness of vitamin K to correct coagulopathy in cirrhosis. This report evaluates data published between 1981 and 2017. Published articles relevant to vitamin K use in cirrhotic patients were reviewed and summarized. The available literature regarding the use of vitamin K in cirrhosis is limited, and the research published so far does not appear to support its use. The routine uses of vitamin K to correct PT/international normalized ratio in hepatic cirrhosis should be avoided unless further studies can demonstrate true clinical benefit.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"131-136"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385738/pdf/ptj4403131.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019428","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Paralyzed by Mistakes - Reassess the Safety of Neuromuscular Blockers in Your Facility.","authors":"Matthew Grissinger","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Neuromuscular blockers have been inadvertently administered to patients who were not receiving proper ventilatory assistance, causing death or permanent injuries.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"91-107"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385733/pdf/ptj4403091.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
James T O'Donnell, James J O'Donnell, F Randy Vogenberg
{"title":"Forensic Analysis in Drug Litigation Finds Most Errors Occur with Commonly Used Therapies and Practices.","authors":"James T O'Donnell, James J O'Donnell, F Randy Vogenberg","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>In the complex setting of obstetrics and reproductive medicine, the medication-related injuries leading to the most litigation involve some of the most commonly used drugs, rather than the newer, more complicated therapies. The authors present a number of cases illustrating how sophisticated treatment of high-risk pregnancies can be jeopardized by a simple negligent act.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"118-121"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385734/pdf/ptj4403118.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193746","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Do GPOs Play a Role in Drug Shortages? Long-Standing Allegations Disputed by The GPOs.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>What role, if any, do group purchasing organizations play in drug shortages?</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"94-121"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385730/pdf/ptj4403094.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Drug and Device News.","authors":"","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Approvals, new indications and formulations, and safety issues.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"95-107"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385731/pdf/ptj4403095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193741","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Pharmaceutical Approval Update.","authors":"Michele B Kaufman","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>Inbrija (levodopa inhalation powder) for oral inhalation for the treatment of \"off\" episodes in Parkinson's disease; Ultomiris (ravulizumab) injection for treating adults with paroxysmal nocturnal hemoglobinuria; and Yupelri (revefenacin) inhalation solution for the maintenance treatment of patients with COPD.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"108-144"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385732/pdf/ptj4403108.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193743","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The 60th American Society of Hematology Annual Meeting & Exposition.","authors":"Walter Alexander","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>We report on two presentations on β-thalassemia and myelodysplastic syndromes, three presentations on chronic lymphocytic leukemia, and others on perioperative oral anticoagulation, sickle-cell anemia, diffuse large B-cell lymphoma, and multiple myeloma.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"138-142"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385735/pdf/ptj4403138.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37019429","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Lowering the Boom on High Drug Prices: HHS Plans Not a Boon to Some Players.","authors":"Stephen Barlas","doi":"","DOIUrl":"","url":null,"abstract":"<p><p>The Trump administration's multipronged effort to use regulatory tools to lower drug prices includes old and new initiatives. But opposition from some players is evident in each instance. Some of that opposition may be based on sound reasoning, some of it may be based on self-interest. The author discusses advertising, protected-class drugs, what's next for rebates, and more.</p>","PeriodicalId":38773,"journal":{"name":"P and T","volume":"44 3","pages":"122-142"},"PeriodicalIF":0.0,"publicationDate":"2019-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6385728/pdf/ptj4403122.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37193747","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}